Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible
To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.
You may also be interested in...
The question of how to develop meta-analyses of clinical trials that can yield useful information on drug and biologic safety will be the subject of an FDA guidance and an important focus of two reports from the Institute of Medicine
FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.